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ORIGINAL ARTICLE
See Editorial by Voors and Lam
BACKGROUND: Patients with heart failure (HF) and atrial fibrillation (AF) 
have higher circulating levels of NT-proBNP (N-terminal pro-B-type natriuretic 
peptide) than HF patients without AF. There is uncertainty about the 
prognostic importance of a given concentration of NT-proBNP in HF patients 
with and without AF. We investigated this question in a large cohort of 
patients with HF and reduced ejection fraction.
METHODS AND RESULTS: We studied 14 737 patients with HF and reduced 
ejection fraction and a measurement of NT-proBNP at time of screening, 
enrolled in either the PARADIGM-HF trial (Prospective Comparison of ARNI 
With ACEI to Determine Impact on Global Mortality and Morbidity in Heart 
Failure) or the ATMOSPHERE trial (Aliskiren Trial to Minimize Outcomes in 
Patients With Heart Failure), of whom 3575 (24%) had AF on their baseline 
ECG. Median (Q1, Q3) levels of NT-proBNP were 1817 pg/mL (1095–3266 pg/
mL) in those with AF and 1271 pg/mL (703–2569 pg/mL) in those without 
(P<0.0001). Patients with AF were older (67 versus 62 years), had worse New 
York Heart Association class (III/IV; 36% versus 24%), and experienced fewer 
previous HF hospitalizations (52% versus 61%) or myocardial infarction (30% 
versus 46%); all P<0.001. We categorized patients with and without AF into 5 
NT-proBNP bands: <400, 400 to 999 (reference), 1000 to 1999, 2000 to 2999, 
and ≥3000 pg/mL. For the primary composite outcome of cardiovascular 
death or HF hospitalization, event rates differed for patients with and without 
AF in the lowest band (<400 pg/mL; 8.2 versus 5.0 per 100 patient-years), 
but not for the higher bands (400–999 pg/mL, 7.4 versus 7.7 per 100 patient-
years; 1000–1999 pg/mL, 9.8 versus 11.4 per 100 patient-year; 2000–2999 
pg/mL, 13.5 versus 13.4 per 100 patient-years; ≥3000 pg/mL, 22.7 versus 
23.0 per 100 patient-years). These findings were consistent whether NT-
proBNP was examined as a categorical or continuous variable and before and 
after adjustment for other prognostic variables. We found similar results for 
the components of the composite outcome and all-cause mortality.
CONCLUSIONS: HF and reduced ejection fraction patients with AF had higher 
NT-proBNP than those without AF. However, above a concentration of 400 pg/
mL (representing most patients in each group), NT-proBNP had similar predictive 
value for adverse cardiovascular outcomes, irrespective of AF status.
CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique 
identifier NCT00853658 (ATMOSPHERE) and NCT01035255 (PARADIGM-HF).
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Levels of natriuretic peptides increase in heart failure (HF) in response to raised myocardial wall stretch and are thought to represent a protective compen-
satory response, inhibiting the renin–angiotensin–al-
dosterone system, stimulating natriuresis and reducing 
vascular tone.1,2
Measurement of natriuretic peptides is recommend-
ed as part of the diagnostic work-up for HF, and they 
may also be used to monitor response to treatment 
and provide prognostic information.3–6 Because higher 
levels are associated with higher rates of cardiovas-
cular death and hospital admission for worsening HF, 
natriuretic peptides are also used to select higher-risk 
patients for inclusion in clinical trials. Many factors are 
known to influence the level of natriuretic peptides, 
including age, obesity, renal function, and atrial fibril-
lation (AF).7–9 Levels of natriuretic peptides are, on 
average, higher in patients with AF, and the prognostic 
significance of a given concentration of B-type natri-
uretic peptide (BNP) or NT-proBNP (N-terminal pro-B-
type natriuretic peptide) in patients with AF, compared 
with those without AF, is uncertain. Because of this 
uncertainty, recent clinical trials in patients with HF and 
reduced ejection fraction (HFrEF) have used different 
natriuretic peptide inclusion thresholds for individuals 
with and without AF, with a higher requirement for 
the former patients. It is hoped that this strategy will 
ensure patients with AF have event rates no less than 
in those without AF. To examine whether this approach 
has any validity, we compared the relationship between 
NT-proBNP concentration and outcomes in patients 
with and without AF using data from 2 contemporary 
trials in patients with HFrEF, each of which had similar 
enrollment criteria.
METHODS
The design, baseline characteristics, and primary results of the 
PARADIGM-HF trial (Prospective Comparison of ARNI With 
ACEI to Determine Impact on Global Mortality and Morbidity 
in Heart Failure) and the ATMOSPHERE trial (Aliskiren Trial to 
Minimize Outcomes in Patients With Heart Failure Trial) are 
published.10–14 Both trials were approved by the ethics com-
mittee at each study center. All patients provided written 
informed consent.
Study Patients
The inclusion criteria for PARADIGM-HF and ATMOSPHERE 
were similar and included New York Heart Association 
(NYHA) functional class II–IV status, ejection fraction of 
≤35% (initially ≤40% for PARADIGM-HF but changed to 
≤35% by amendment), and a plasma BNP of ≥150 pg/
mL or NT-proBNP of ≥600 pg/mL. In both trials, patients 
who had been hospitalized for HF within the preceding 12 
months could be enrolled with a lower natriuretic peptide 
concentration (BNP ≥100 pg/mL or NT-proBNP ≥400 pg/mL). 
Plasma NT-proBNP was measured in a core laboratory with 
the Roche Elecsys proBNP assay (Roche Diagnostics GmbH, 
Mannheim, Germany), with a coefficient of variation <2.5% 
at all levels tested.
Patients were required to be taking an angiotensin-con-
verting enzyme inhibitor or angiotensin receptor blocker at a 
dose equivalent to enalapril 10 mg daily for at least 4 weeks 
before screening, along with a stable dose of a β-blocker 
(unless contraindicated or not tolerated) and a mineralocor-
ticoid receptor antagonist if indicated. The exclusion criteria 
included history of intolerance of an angiotensin-converting 
enzyme inhibitor or angiotensin receptor blocker, symptom-
atic hypotension (or a systolic blood pressure <100 mm Hg 
at screening/<95 mm Hg at randomization), an estimated 
glomerular filtration rate <30 mL/min per 1.73 m2 (<40 
mL/min per 1.73 m2 for ATMOSPHERE), a serum potas-
sium concentration of >5.2 mmol/L at screening and >5.4 
mmol/L at randomization in PARADIGM-HF and; >5.0 and 
>5.2 mmol/L, respectively, in ATMOSPHERE), or a history of 
angioedema.
Study Procedures
In both PARADIGM-HF and ATMOSPHERE, patients first 
received enalapril (5 or)10 mg BID (single-blind) and then 
sacubitril/valsartan (single-blind) for an additional 4 to 
6 weeks in PARADIGM-HF and aliskiren plus enalapril in 
ATMOSPHERE. In PARADIGM-HF, patients tolerating both 
drugs at target doses were randomly assigned to enala-
pril 10 mg BID or sacubitril/valsartan 200 mg BID, and in 
ATMOSPHERE, patients who tolerated both drugs were 
WHAT IS NEW?
• Contemporary heart failure trials require a higher 
enrollment BNP/NT-proBNP (N-terminal pro-B-type 
natriuretic peptide) concentration in patients with 
atrial fibrillation, compared with those without 
atrial fibrillation. The principal assumption behind 
this approach is that patients with atrial fibrillation 
are at a lower risk of cardiovascular events for a 
given level of BNP/NT-proBNP than patients with-
out atrial fibrillation with the same BNP/NT-proBNP 
concentration.
• Our findings, obtained from several randomized, 
controlled heart failure trials, suggest that this is 
incorrect.
WHAT ARE THE CLINICAL  
IMPLICATIONS?
• These findings are important for future design of 
clinical trials in heart failure but also relevant to 
everyday clinical practice.
• Our findings are robust as they are derived from 
a very large data set and are clinically relevant as 
they now inform physicians that the increment in 
risk related to higher BNP/NT-proBNP concentra-
tions is similar in all patients with heart failure and 
reduced ejection fraction, irrespective of rhythm.
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randomized in a 1:1:1 ratio to receive (1) combination of 
5 or 10 mg enalapril BID and aliskiren 150 mg OD (com-
bination group), (2) aliskiren 150 mg OD, (3) enalapril 5 or 
10 mg BID. The dose of enalapril was selected based on 
its effect to reduce the risk of death compared with pla-
cebo in the SOLVD treatment trial (Studies of Left Ventricular 
Dysfunction).15
Baseline NT-proBNP
We examined the relationship between baseline NT-proBNP 
category (NT-proBNP bands) and outcomes using NT-proBNP 
as a continuous measure (modeled as a restricted cubic 
spline—see below). Baseline NT-proBNP was measured at 
time of screening in each of the 2 trials. We defined the fol-
lowing NT-proBNP bands at baseline: <400, 400 to 999 (refer-
ence group), 1000 to 1999, 2000 to 2999, and ≥3000 pg/
mL and applied these bands separately in patients with and 
without AF.
Outcomes
In the present article, we focused on the primary end point of 
both trials, which was the first occurrence of cardiovascular 
death or HF hospitalization, as well as each of the compo-
nents separately. We also report death from any cause, which 
was a secondary end point in PARADIGM-HF and a prespeci-
fied exploratory outcome in ATMOSPHERE.
Statistical Analysis
Baseline characteristics are presented as means with SDs 
for continuous variables and frequencies and percentages 
for categorical variables. Unadjusted and age-adjusted 
event rates are reported per 100 patient-years of follow-
up according to AF status and NT-proBNP band. Cox pro-
portional hazard models were applied to calculate hazard 
ratios and cumulative event curves according to the level 
of NT-proBNP with patients with 400 to 999 pg/mL as ref-
erence, in patients with and without AF, respectively. The 
adjusted Cox regression models included information on 
age, sex, race (white versus all other), geographical region, 
study drug, NYHA class, ejection fraction, heart rate, sys-
tolic blood pressure, body mass index, estimated glomerular 
filtration rate, HF duration, ischemic cause, history of recent 
HF hospitalization, and history of myocardial infarction. Log 
(−log(survival)) curves were used to evaluate the propor-
tional hazard assumption. The assumption of linearity of 
continuous variables (age) was tested by including a variable 
of age squared. These were found to valid unless otherwise 
specified. NT-proBNP as a continuous variable and the out-
comes of interest, according to the presence of AF, adjusted 
for other prognostic variables, is shown with NT-proBNP 
modeled as a restricted cubic spline (NT-proBNP, 600 pg/mL 
is the reference value). Furthermore, we repeated analyses 
in each trial separately. BNP was only available for patients 
in PARADIGM-HF, and similar analyses for that natriuretic 
peptide in that trial are included in the Data Supplement. 
All P values are 2-sided, and a P value of <0.05 was consid-
ered significant. Analyses were performed using Stata ver-
sion 14 (Stata Corp., College Station, TX) and SAS version 
9.4 (SAS Institute, NC).
RESULTS
A total of 14 737 patients had a measurement of NT-
proBNP at baseline, of whom 3575 (24%) had AF 
on their baseline ECG. Median (Q1, Q3) levels of NT-
proBNP were 1817 pg/mL (1095, 3266) in those with 
AF and 1271 pg/mL (703, 2569) in those without AF 
(P<0.0001). Patients with AF were older (67 versus 
62 years, respectively), were more often white (81% 
versus 60%), had worse functional status (NYHA class 
III/IV; 36% versus 24%) but were less likely to have a 
previous HF hospitalization (52% versus 61%), a his-
tory of myocardial infarction (30% versus 46%), and 
implantable cardioverter defibrillator (8% versus 13%), 
all P<0.001 (Table 1).
Clinical Outcomes According to  
NT-proBNP
The clinical outcomes of interest, according to the base-
line NT-proBNP category, are summarized in Table  2. 
The rate of the composite outcome, each of its com-
ponents, and all-cause death were significantly higher 
in patients with levels of NT-proBNP >1000 pg/mL than 
in patients with levels of NT-proBNP with 400 to 999 
pg/mL as reference. There was a step-wise increase in 
the risk of the primary composite outcome across the 5 
predefined NT-proBNP bands in each of the 2 groups of 
patients (with and without AF). The only exception was 
in patients with AF in the 2 lowest bands (<400 and 
400–999 pg/mL) where rates and risk did not differ sig-
nificantly between bands although there were very few 
patients with AF (and even fewer events) in the lowest 
NT-proBNP band. In these 2 lowest NT-proBNP bands, 
there was significant interaction between AF status and 
risk of the primary outcome and all-cause mortality.
In patients with NT-proBNP >3000 pg/mL, the rate 
of the primary composite outcome was 23.0 per 100 
patient-year in patients without AF and 22.7 per 100 
patient-year in those with AF; the adjusted hazard 
ratio, compared with individuals in the 400 to 999 pg/
mL band, was 2.73 (2.46–3.03) and 2.91 (2.37–3.58), 
respectively (P value for interaction between the risk of 
the primary outcome and the presence or absence of AF, 
0.125). No interaction between AF status and NT-proB-
NP band was found for the other outcomes or when 
each trial was analyzed separately (data not shown). For 
age-adjusted event rates, we found a significant differ-
ence according to AF status for the primary outcome 
and all-cause death in patients with NT-proBNP <400 
pg/mL (P=0.002 both), but not for the outcomes of car-
diovascular death and HF hospitalization. No significant 
differences in age-adjusted rates according to AF status 
were found in the higher NT-proBNP bands.
A similar pattern was seen for each of the compo-
nents of the primary composite outcome and all-cause 
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Table 1. Baseline Characteristics According to the Presence of AF on Baseline ECG
 No AF on ECG, n=11 162 AF on ECG, n=3575 P Value
Age, mean, y 62±12 67±11 <0.001
Female sex, n (%) 2487 (22) 702 (20) <0.001
White, n (%) 6729 (60) 2894 (81) <0.001
Region, n (%)   <0.001
  North America 657 (6) 109 (3)  
  Western Europe 1977 (18) 432 (12)  
  Eastern Europe 2776 (25) 910 (26)  
  South America 2844 (26) 1874 (45)  
  Asia 2908 (26) 524 (13)  
Ejection fraction, % 28.6±6.1 29.1±5.5 <0.001
Systolic blood pressure, mm Hg 122±17 123±16 0.0002
Heart rate/min 71±11 76±14 <0.001
Body mass index 27.4±5.4 29.1±5.5 <0.001
Current smoker, n (%) 1663 (15) 361 (10) <0.001
NYHA class, n (%)   <0.001
  I 480 (4) 71 (2)  
  II 8088 (73) 2211 (62)  
  III 2512 (23) 1246 (35)  
  IV 73 (1) 43 (1)  
Laboratory measurements    
  eGFR, mL/min per 1.73 m2, median (Q1, Q3) 70 (57, 84) 66 (55, 80) <0.001
  CKD (eGFR<60 mL/min per 1.73 m2) 3254 (29) 1238 (35) <0.001
  NT-proBNP pg/mL, median (Q1, Q3) 1271 (703, 2569) 1817 (1095, 3266) <0.001
   <400 pg/mL 886 (8) 90 (3)  
   400–999 pg/mL 3543 (32) 676 (19)  
   1000–1999 pg/mL 3087 (28) 1181 (33)  
   2000–2999 pg/mL 1315 (12) 628 (18)  
   ≥3000 pg/mL 2331 (21) 1000 (28)  
Medical history, n (%)    
  Prior HF hospitalization 6451 (61) 2159 (52) <0.001
  Myocardial infarction 5182 (46) 1053 (30) <0.001
  Hypertension 7138 (64) 2699 (76) <0.001
  Stroke 813 (7) 351 (10) <0.001
  COPD 1296 (12) 479 (13) 0.003
  Diabetes mellitus 3632 (33) 1112 (31) 0.015
  ICD 1452 (13) 269 (8) <0.001
  CRT 798 (7) 129 (4) <0.001
Pharmacotherapy, n (%)    
  β-blocker 10 323 (93) 3294 (92) 0.4999
  Diuretic 8775 (79) 3051 (85) <0.001
  MRA 5269 (47) 1747 (49) 0.0833
  Digoxin 2742 (25) 1841 (52) <0.001
  Amiodarone 1117 (10) 280 (8) 0.001
  Statin 6471 (58) 1558 (44) <0.001
AF indicates atrial fibrillation; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CRT, cardiac 
resynchronization therapy; eGFR, estimate glomerular filtration rate; HF, heart failure; ICD, implantable cardioverter defibrillator; 
MRA, mineralocorticoid receptor antagonist; NT-proBNP, N-terminal pro-B-type natriuretic peptide; and NYHA, New York Heart 
Association functional class.
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Table 2. Outcomes of Interest According to the Presence of AF at Baseline and Bands of NT-proBNP
Outcome/NT-
proBNP Band 
(pg/ml) 
No AF on ECG AF on ECG
P for 
Interact.
Events/ 
Patients
Event 
Rate 
Per 100 
py
Age-Adj. 
Event 
Rate Per 
100 py
Unadjusted 
HR (95% 
CI)
Adjusted
HR (95% 
CI)
Events/ 
Patients
Event 
Rate 
Per 100 
py
Age-Adj. 
Event 
Rate
Per 100 py
Unadjusted
HR (95% 
CI)
Adjusted
HR (95% 
CI)  
CV death or 
HF hosp.,
3153/11 162 11.7 11.8   1087/3575 12.8 12.8   0.125
  ≤400
138/886 5.0 4.2
0.66  
(0.55–0.79)
0.65  
(0.54–0.78)
20/90 8.2 6.7
1.11  
(0.70–1.78)
1.11  
(0.69–1.78)
 
  400–999
721/3542 7.7 7.7
1.00  
(Ref.)
1.00  
(Ref.)
136/676 7.4 7.3 1.00 (Ref.) 1.00 (Ref.)  
  1000–1999
844/3087 11.4 11.4
1.48  
(1.34–1.63)
1.42  
(1.28–1.57)
298/1181 9.8 9.9
1.32  
(1.08–1.61)
1.34  
(1.09–1.65)
 
  2000–2999
434/1315 14.8 14.9
1.91  
(1.70–2.15)
1.81  
(1.60–2.04)
200/628 13.5 13.9
1.80  
(1.45–2.24)
1.80  
(1.44–2.25)
 
  ≥3000
1016/2331 23.0 23.1
2.96  
(2.69–3.26)
2.73  
(2.46–3.03)
433/1000 22.7 23.3
2.96  
(2.44–3.59)
2.91  
(2.37–3.58)
 
CV death 2042/11 162 7.0 7.1   730/3575 7.8 7.6   0.134
  ≤400
902/886 3.2 3.2
0.75  
(0.60–0.94)
0.73  
(0.58–0.91)
15/90 5.9 4.7
1.27  
(0.74–2.20)
1.23  
(0.71–2.13)
 
  400–999 413/3542 4.1 4.1 1.00 (Ref.) 1.00 (Ref.) 89/676 4.6 4.5 1.00 (Ref.) 1.00 (Ref.)  
  1000–1999
513/3087 6.3 6.4
1.55  
(1.36–1.76)
1.48  
(1.30–1.69)
191/1181 5.8 5.8
1.28  
(1.00–1.65)
1.24  
(0.96–1.60)
 
  2000–2999
281/1315 8.6 8.7
2.10  
(1.81–2.45)
1.92  
(1.64–2.24)
138/628 8.5 8.6
1.89  
(1.45–2.46)
1.77  
(1.35–2.33)
 
  ≥3000
745/2331 14.8 14.8
3.67  
(3.25–4.14)
3.15  
(2.77–3.59)
297/1000 13.2 13.5
2.98  
(2.35–3.78)
2.68  
(2.08–3.46)
 
HF 
hospitalization
1798/111 62 6.7 6.7   630/3575 7.4 7.4   0.267
  ≤400
75/886 2.7 2.7
0.60  
(0.47–0.77)
0.61  
(0.47–0.78)
10/90 4.1 3.0
1.03  
(0.53–1.99)
1.06  
(0.55–2.06)
 
  400–999 433/3542 4.6 4.6 1.00 (Ref.) 1.00 (Ref.) 74/676 4.0 4.0 1.00 (Ref.) 1.00 (Ref.)  
  1000–1999
493/3087 6.6 6.7
1.43  
(1.25–1.62)
1.37  
(1.21–1.57)
173/1181 5.7 5.8
1.39  
(1.06–1.83)
1.45  
(1.10–1.92)
 
  2000–2999
227/1315 7.7 7.8
1.65  
(1.40–1.93)
1.61  
(1.36–1.90)
116/628 7.7 8.0
1.88  
(1.41–2.52)
1.88  
(1.39–2.54)
 
  ≥3000
570/2331 12.9 13.0
2.72  
(2.40–3.08)
2.65  
(2.32–3.03)
257/1000 13.5 14.1
3.10  
(2.39–4.02)
3.17  
(2.40–4.18)
 
All-cause 
mortality
2439/11 162 8.3 8.5   881/3575 9.4 9.1   0.102
  ≤400
110/886 3.9 3.9
0.74  
(0.60–0.91)
0.74  
(0.60–0.92)
23/90 9.0 6.7
1.63  
(1.04–2.55)
1.52  
(0.96–2.41)
 
  400–999
508/3543 5.1 5.1
1.00  
(Ref.)
1.00  
(Ref.)
107/676 5.5 5.4 1.00 (Ref.) 1.00 (Ref.)  
  1000–1999
623/3087 7.7 7.8
1.53  
(1.36–1.72)
1.46  
(1.30–1.65)
234/1181 7.1 7.0
1.30  
(1.04–1.64)
1.23  
(0.98–1.55)
 
  2000–2999
340/1315 10.4 10.5
2.07  
(1.81–2.38)
1.89  
(1.64–2.18)
167/628 10.3 10.4
1.90  
(1.49–2.42)
1.72  
(1.34–2.21)
 
  ≥3000
858/2331 17.0 17.2
3.44  
(3.09–3.85)
2.99  
(2.65–3.36)
350/1000 15.5 15.5
2.91  
(2.34–3.62)
2.52  
(2.00–3.17)
 
Adjusted for age, sex, race (white vs. all other), study drug, geographical region, New York Heart Association class, ejection fraction, heart rate, systolic blood 
pressure, body mass index, estimated glomerular filtration rate (eGFR), HF duration, ischemic cause, history of recent HF hospitalization, and history of myocardial 
infarction. AF indicates atrial fibrillation; CI, confidence interval; CV, cardiovascular; HF hosp., heart failure hospitalization; HR, heart rate; NT-proBNP, N-terminal 
pro-B-type natriuretic peptide; and py, patient-year.
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mortality, with no significant interaction AF status and 
outcome for each NT-proBNP category (Table  2; Fig-
ure 1). The relation between NT-proBNP as a continuous 
variable and the outcomes of interest, according to the 
presence of AF, adjusted for other prognostic variables 
and with NT-proBNP of 600 pg/mL as the reference val-
ue is shown in Figure 2. Analyses of BNP in PARADIGM-
HF showed very similar findings to those of NT-proBNP 
in PARADIGM-HF and ATMOSPHERE combined (Table I 
in the Data Supplement).
Figure 1. Forest plot of relation between baseline NT-proBNP (N-terminal pro-B-type natriuretic peptide) and out-
comes in patients with and without atrial fibrillation.  
Adjusted for age, sex, race (white vs all other), study drug, geographical region, New York Heart Association class, ejection 
fraction, heart rate, systolic blood pressure, body mass index, estimated glomerular filtration rate (eGFR), heart failure (HF) du-
ration, ischemic cause, history of recent HF hospitalization, and history of myocardial infarction. AF indicates atrial fibrillation; 
and CV, cardiovascular.
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Figure 2. Restricted cubic splines of relation between baseline NT-proBNP (N-terminal pro-B-type natriuretic peptide) 
and outcomes in patients with and without atrial fibrillation.  
Interaction P values: Primary composite end point, P=0.1541; cardiovascular death, P=0.4349; heart failure hospitalization P=0.6869; 
all-cause mortality,P=0.4164. Adjusted for age, sex, race (white vs. all other), study drug, geographical region, New York Heart Asso-
ciation class, ejection fraction, heart rate, systolic blood pressure, body mass index, estimated glomerular filtration rate, heart failure 
(HF) duration, ischemic cause, history of recent HF hospitalization, and history of myocardial infarction. AF indicates atrial fibrillation.
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DISCUSSION
In this analysis, which included a large number of patients 
with HFrEF, we found that a given concentration of NT-
proBNP was associated with a similar risk of cardiovascular 
death or hospitalization for HF in patients with and with-
out AF. Patients with AF were less likely, however, to have 
a low NT-proBNP concentration. Our finding of similar risk 
related to NT-proBNP level was true whether comparing 
unadjusted outcomes or outcomes adjusted for other 
prognostic variables, some of which differed notably 
between patients with and without AF. These observa-
tions call into question the now common policy of requir-
ing patients with AF to have a higher qualifying NT-proB-
NP (or BNP) for enrollment in clinical trials and the implicit 
assumption that a given natriuretic peptide concentration 
is not as predictive of an adverse outcome in patents with 
AF compared with those without. Our data show this not 
to be true, at least over the range from 400 pg/mL to 8000 
pg/mL. Among individuals with a NT-proBNP of ≤400 pg/
mL, patients without AF had lower events rates than those 
with AF (no clear differences were seen between patients 
with and without AF in any of the NT-proBNP bands >400 
pg/mL). It is uncertain whether this apparent difference at 
NT-proBNP levels of <400 pg/mL is real or not and may just 
reflect the small numbers of patients (n=90) and events 
(n=20 patients with either cardiovascular death or HF hos-
pitalization) in the AF group in this low NT-proBNP band. 
In any case, for clinical trials at least, this remaining uncer-
tainty could be obviated simply by enrolling only patients 
with a NT-proBNP of >400 pg/mL.
There is a related question to consider. Do the same 
relationships apply for other natriuretic peptides? In a 
small study, in patients with more advanced HF (NYHA 
class III-IV), AF was an independent determinant of NT-pro-
ANP (N-terminal proatrial natriuretic peptide), but not of 
NT-proBNP levels, raising the possibility that atrial derived 
peptides might show different discrimination.16 For BNP, 
we found the predictive value to be similar irrespective 
of AF status although only derived from patients in the 
PARADIGM-HF trial (Table I in the Data Supplement).
The explanation for our finding and why it contradicts 
conventional thinking is uncertain. Patients with AF had 
more adverse prognostic characteristics at baseline (eg, old-
er age, worse NYHA class, and lower estimated glomerular 
filtration rate) and, for an equivalent level of NT-proBNP, 
their risk would have been greater than patients without 
AF had they been in sinus rhythm. In other words, their 
similar net risk to the overall risk in individuals without AF 
could have reflected a higher non–NT-proBNP–related risk 
and lower NT-proBNP–related risk. Apart from the unlikely 
scenario that these opposing risks would cancel each other 
out, adjusting for other prognostic factors did not mean-
ingfully change the risk related to NT-proBNP in patients 
with AF (or in those without AF), probably reflecting the 
pre-eminence of natriuretic peptides as prognostic mark-
ers in HF. We used a separate reference group (NT-proBNP 
400–999 pg/mL) in each of the 2 rhythm groups rather 
than a single reference group for all patients. Because the 
event rates were similar in this NT-proBNP band for each 
rhythm group, the use of 2 reference groups rather than 1 
reference group did not change the interpretation of our 
findings. However, the relative risk for higher NT-proBNP 
bands within each rhythm stratum could have looked dif-
ferent had the event rate in 1 reference group been sig-
nificantly higher or lower than in the other rhythm group.
We think our finding is important for clinical prac-
tice and, especially, for clinical trials in HFrEF. Physicians 
should not assume a higher natriuretic peptide concen-
tration in a patient with AF merely reflects the pres-
ence of the arrhythmia and does not have the prognos-
tic significance of the same level in a patient without 
AF—such thinking will underestimate the patients risk. 
Similarly, requirement for a higher entry natriuretic 
peptide threshold in patients with AF to enter a clini-
cal trial, where the natriuretic peptide concentration is 
used as a means of ensuring a higher event rate, does 
not make sense and may result in a needlessly large 
screening-failure rate. These considerations may be 
different in HF and preserved ejection fraction where 
natriuretic peptides provide greater diagnostic security 
than in HFrEF as there is no investigative equivalent to a 
reduced EF in HF and preserved ejection fraction.17
Limitations
The current study has several limitations. It is a retro-
spective analysis, and the NT-proBNP bands used were 
not predefined. The fact that elevated BNP or NT-proB-
NP was required to get included in the study hampers 
the interpretation of the results in the lower bands. Our 
findings relate to HFrEF and whether the same is true 
for HF and preserved ejection fraction is not known. We 
only had data for BNP in PARADIGM-HF, which make 
these results less reliable.
Conclusions
In summary, above a concentration of 400 pg/mL, any 
given concentration of NT-proBNP had a similar predic-
tive value for adverse outcomes in HFrEF patients with 
and without AF. Although NT-proBNP levels are, on 
average, higher in patients with AF, this does not dimin-
ish their prognostic import.
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